{"id":"aminodiphenylhydantoin-valeric-acid","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"N03AB03","category":"atc"},{"label":"Active","category":"status"},{"label":"Epilepsy","category":"indication"}],"phase":"unknown","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"neocitrullamon","offLabel":[],"synonyms":["amino(diphenylhydantoin) valeric acid","Neo-citrullamin","neocitrullamon"],"timeline":[],"brandName":"Neocitrullamon","ecosystem":[{"indication":"Epilepsy","otherDrugs":[{"name":"amobarbital","slug":"amobarbital","company":""},{"name":"carbamazepine","slug":"carbamazepine","company":"Novartis"},{"name":"diazepam","slug":"diazepam","company":"Roche"},{"name":"felbamate","slug":"felbamate","company":"Meda Pharms"}],"globalPrevalence":50000000}],"mechanism":{"modality":"Small Molecule","explanation":"Imagine your brain cells are like a rowdy crowd - they're always excited and moving around. Neocitrullamon helps calm them down by making it harder for them to get too excited, which can help prevent seizures. This is done by changing the way the cells' membranes work, making it harder for them to fire off signals too quickly.","oneSentence":"Neocitrullamon is thought to work by stabilizing neuronal membranes and reducing excitability.","technicalDetail":"Neocitrullamon is believed to exert its effects by modulating the activity of voltage-gated ion channels, particularly sodium channels, which play a critical role in the generation and propagation of action potentials in neurons."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5053","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=amino(diphenylhydantoin) valeric acid","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:43:01.727388","biosimilars":[],"competitors":[{"drugName":"ethotoin","drugSlug":"ethotoin","fdaApproval":"1957-04-22","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"phenytoin","drugSlug":"phenytoin","fdaApproval":"1953-01-06","genericCount":7,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"mephenytoin","drugSlug":"mephenytoin","fdaApproval":"1946-10-23","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"fosphenytoin","drugSlug":"fosphenytoin","fdaApproval":"1996-08-05","patentExpiry":"Mar 13, 2029","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"amino(diphenylhydantoin) valeric acid","indications":{"approved":[{"name":"Epilepsy","source":"DrugCentral","snomedId":84757009,"regulator":"FDA","usPrevalence":3400000,"globalPrevalence":50000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"ethotoin","brandName":"ethotoin","genericName":"ethotoin","approvalYear":"1957","relationship":"same-class"},{"drugId":"phenytoin","brandName":"phenytoin","genericName":"phenytoin","approvalYear":"1953","relationship":"same-class"},{"drugId":"mephenytoin","brandName":"mephenytoin","genericName":"mephenytoin","approvalYear":"1946","relationship":"same-class"},{"drugId":"fosphenytoin","brandName":"fosphenytoin","genericName":"fosphenytoin","approvalYear":"1996","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"7L5LMT7B2H","CHEBI":"CHEBI:134734","UMLSCUI":"C3652632","ChEMBL_ID":"CHEMBL3707389","DRUGBANK_ID":"DB13396","PUBCHEM_CID":"3084726"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"N03AB03","allCodes":["N03AB03"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Neocitrullamon, also known as amino(diphenylhydantoin) valeric acid, is a small molecule modality with unknown drug class and target. It is approved for the treatment of epilepsy, but its commercial status and key safety considerations are currently unknown. Further research is needed to fully understand its pharmacological properties and potential risks. Neocitrullamon's exact mechanism of action is unclear, but it is believed to work by stabilizing neuronal membranes and reducing excitability. Its development and approval status are also unclear.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":false,"score":2}}